Morgan Stanley assumed coverage of Acadia Pharmaceuticals (ACAD) with an Equal Weight rating and $20 price target The firm sees patent protection for Nuplazid extending to 2030 and models about $2.4B in residuals post loss of exclusivity, noting that it models 11% net product sales growth in 2025 to about $1.1B.
Kens
Morgan Stanley assumed coverage of Acadia Pharmaceuticals (ACAD)...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1215 | $12.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.54 | 804 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |